Fate Therapeutics Inc (FATE)

[jondoeuk]

ASH abstracts

Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed / Refractory B-Cell Lymphoma https://ash.confex.com/ash/2021/webprogram/Paper151185.html

Off-the-Shelf, Multiplexed-Engineered iPSC-Derived NK Cells Mediate Potent Multi-Antigen Targeting of B-Cell Malignancies with Reduced Cytotoxicity Against Healthy B Cells https://ash.confex.com/ash/2021/webprogram/Paper148654.html

Arming of iPSC-Derived NK Cells Expressing a Novel CD64 Fusion Receptor with Therapeutic Antibodies Represents a Novel Off-the-Shelf, Antigen-Targeting Strategy for Cancer https://ash.confex.com/ash/2021/webprogram/Paper148642.html

Phase I Study of FT516, an Off-the-Shelf, iPSC-Derived NK Cell Therapy, in Combination with Rituximab in Patients with Relapsed / Refractory B-Cell Lymphoma https://ash.confex.com/ash/2021/webprogram/Paper151520.html

Clinical Manufacture of FT819: Use of a Clonal Multiplexed-Engineered Master Induced Pluripotent Stem Cell Line to Mass Produce Off-the-Shelf CAR T-Cell Therapy https://ash.confex.com/ash/2021/webprogram/Paper152985.html

Combination of Three Unique Anti-Tumor Modalities Engineered into iPSC-Derived T Cells Demonstrate a Synergistic Effect in Overcoming Tumor Heterogeneity and Cancer Escape https://ash.confex.com/ash/2021/webprogram/Paper153268.html

Dual Chimeric Antigen Receptor Approach Combining Novel Tumor Targeting Strategies Circumvents Antigen Escape in Multiple Myeloma https://ash.confex.com/ash/2021/webprogram/Paper154025.html

Off-the-Shelf, iPSC-Derived CAR NK Cells Multiplexed-Engineered for the Avoidance of Allogeneic Host Immune Cell Rejection https://ash.confex.com/ash/2021/webprogram/Paper153484.html